Accelmed Partners II

Accelmed Partners II is a private equity firm based in Miami, Florida, focusing on acquiring and investing in U.S. commercial-stage, lower middle market HealthTech companies. The firm seeks to accelerate value and scale innovation across the HealthTech field by leveraging its deep industry experience, operational and financial expertise, and strong global relationships. Accelmed Partners II closed its second fund at $400 million in March 2021, exceeding its original $300 million target.

The firm's investment strategy emphasizes control-oriented opportunities in companies with revenues typically between $20 million and $70 million. Accelmed Partners II focuses on sectors such as medical devices, diagnostics, digital health, and technology-enabled healthcare services. The firm has a track record of successful investments, including the acquisition of TearLab, a leader in ocular surface diagnostics for dry eye disease, and leading a $67 million financing round to support the commercial expansion of NeuroPace, a developer of brain technology for individuals with neurological disorders.

Accelmed Partners II's approach involves working closely with management teams to enhance operations, update product portfolios, and revamp commercial organizations within their portfolio companies. This collaborative strategy aims to improve healthcare delivery and patient outcomes by supporting innovative solutions that enhance the efficiency and personalization of medical care.